Critical Outcome Technologies applies for orphan drug designation for COTI-2 treatment of ovarian cancer


Friday, 4 Apr 2014 09:00am EDT 

Critical Outcome Technologies Inc:Says it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for lead cancer drug candidate, COTI-2, for the treatment of ovarian cancer. 

Company Quote